Compared with the data published by accredited HFUs in the SEC-EXCELENTE programme [5], at our centre, at the end of the follow-up period, there was a higher prescription rate for drugs with prognostic benefits for HF, including angiotensin receptor–neprilysin inhibitor (59% vs. 40.7%), mineralocorticoid receptor antagonists (70.1% vs. 56.9%), beta-blockers (87.3% vs. 80.5%), ivabradine (19.5% vs. 7.9%), and a lower prescription of loop diuretics (71.5% vs. 82.9%). This evidence concerns the gene NR3C2 and hydrops fetalis.